Pennsylvania Compounder Calls for Oxitriptan’s Inclusion on 503A List

Drug Industry Daily
A A
Pennsylvania compounder Summit Health Pharmacy has petitioned the FDA to include oxitriptan on the agency’s 503A bulk substances list—and says the agency should also allow it for compounding in the meantime.

To View This Article:

Login

Subscribe To Drug Industry Daily